BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31614143)

  • 1. Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner.
    Moody TW; Lee L; Ramos-Alvarez I; Jensen RT
    Eur J Pharmacol; 2019 Dec; 865():172735. PubMed ID: 31614143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
    Moody TW; Chan DC; Mantey SA; Moreno P; Jensen RT
    Life Sci; 2014 Mar; 100(1):25-34. PubMed ID: 24496038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
    Moody TW; Ramos-Alvarez I; Moreno P; Mantey SA; Ridnour L; Wink D; Jensen RT
    Peptides; 2017 Apr; 90():90-99. PubMed ID: 28153500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3.
    Moody TW; Ramos-Alvarez I; Jensen RT
    Peptides; 2022 Oct; 156():170858. PubMed ID: 35932909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.
    Moody TW; Osefo N; Nuche-Berenguer B; Ridnour L; Wink D; Jensen RT
    J Pharmacol Exp Ther; 2012 Jun; 341(3):873-81. PubMed ID: 22389426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.
    Moody TW; Lee L; Iordanskaia T; Ramos-Alvarez I; Moreno P; Boudreau HE; Leto TL; Jensen RT
    Peptides; 2019 Oct; 120():170017. PubMed ID: 30273693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
    Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
    Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.
    Moody TW; Sancho V; di Florio A; Nuche-Berenguer B; Mantey S; Jensen RT
    Peptides; 2011 Aug; 32(8):1677-84. PubMed ID: 21712056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells.
    Müller KM; Tveteraas IH; Aasrum M; Ødegård J; Dawood M; Dajani O; Christoffersen T; Sandnes DL
    BMC Cancer; 2011 Oct; 11():421. PubMed ID: 21961726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer.
    Moody TW; Ramos-Alvarez I; Jensen RT
    Biology (Basel); 2023 Jul; 12(7):. PubMed ID: 37508387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.
    Moody TW; Berna MJ; Mantey S; Sancho V; Ridnour L; Wink DA; Chan D; Giaccone G; Jensen RT
    Eur J Pharmacol; 2010 Jul; 637(1-3):38-45. PubMed ID: 20388507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The G Protein-Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3.
    Moody TW; Lee L; Jensen RT
    J Mol Neurosci; 2021 Aug; 71(8):1589-1597. PubMed ID: 32964398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NADPH-oxidase-dependent reactive oxygen species mediate EGFR transactivation by FPRL1 in WKYMVm-stimulated human lung cancer cells.
    Cattaneo F; Iaccio A; Guerra G; Montagnani S; Ammendola R
    Free Radic Biol Med; 2011 Sep; 51(6):1126-36. PubMed ID: 21708247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells.
    Leyton J; Garcia-Marin L; Jensen RT; Moody TW
    Eur J Pharmacol; 2002 May; 442(3):179-86. PubMed ID: 12065070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
    Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
    Int J Cancer; 2011 Nov; 129(10):2408-16. PubMed ID: 21207425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells.
    Ushio-Fukai M; Griendling KK; Becker PL; Hilenski L; Halleran S; Alexander RW
    Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):489-95. PubMed ID: 11304462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation.
    Touyz RM; Cruzado M; Tabet F; Yao G; Salomon S; Schiffrin EL
    Can J Physiol Pharmacol; 2003 Feb; 81(2):159-67. PubMed ID: 12710530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.